retatrutide weight loss trial retatrutide Eli Lilly's shows promising results in phase 3 Retatrutide for Weight Loss: 2026

However, MAD does not include a specific induction protocol, but a reduction of carbohydrate intake to 1020 g per day is scheduled

Andersen, Frederik

The team also has bigger goals for the future

Before you and your care team add GLP-1s, heres what experts say you should think about: You Might Finally Be Able to Get Help for Your Other Health Conditions Unfortunately, many people with bipolar disorder meet the on-label criteria for GLP-1s like obesity or type 2 diabetes yet are not being treated, says McIntyre

Patients seeking predictable, flat-rate pricing will appreciate Levitys simple cost structure

One example is Orforglipron, an oral GLP-1 candidate from Lilly that recently completed Phase 3 clinical trials for weight management